Navigation Links
Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
Date:8/19/2007

BERKELEY, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the U.S. Patent Office has issued the company a broad composition of matter patent covering the company's proprietary second-generation TLR9 agonists.

The claims cover a broad class of novel TLR9 agonists containing short DNA sequences separated by spacer molecules. These linear chimeric immunomodulatory compounds (CICs), are being developed at Dynavax for application across a wide range of therapeutic categories. The claims cover CICs with or without antigen, and alone or in a pharmaceutical preparation. The current term for this patent expires in June 2022. The patent, U.S. patent No. 7,255,868 B2, was issued August 14, 2007 with inventors Karen Fearon, Dino Dina, M.D., and Stephen Tuck.

According to Dino Dina, M.D., President and Chief Executive Officer, "We developed the second-generation TLR9 agonists specifically to gain broad patent coverage for a full range of products in our pipeline. The issuance of this landmark patent provides broad patent coverage for novel and non-obvious molecules that are completely different from our first generation TLR9 agonists. We have pending applications in this family that we believe have the potential to expand the scope of coverage."

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which ar
'/>"/>

SOURCE Dynavax Technologies Corporation

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2

Related biology technology :

1. Landmark patent law under attack, Bayh says
2. Changes to U.S. patent law must nurture our culture of innovation
3. WARF questions relevancy of documents used to uphold patent challenge
4. Supreme Court limits foreign reach of U.S. patents
5. High court sends message on patent obviousness
6. Supreme Court ruling seen as blow to WARF stem cell patents
7. Patent licensing: For enforcing companies, the rules have changed
8. Patent ruling doesnt tarnish Wisconsins stem cell leadership
9. Heres why Wisconsins stem cell patents are being challenged
10. WARF is likely to hold on to stem cell patent rights
11. Patent office upholds challenge to WARF stem cell patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...Newswire/ -- BioTrends Research Group, Inc.,releas...M) publication, a,syndicated report offering compr...ia and bone and mineral metabolism in Chronic Kidn... information from 182 US,Nephrologists -- data wer...ne 2008., In the renal anemia market, while the u...
(Date:7/25/2008)...X, CALGARY, July 25 / Resv...X:RVX) is pleased to announce effective,immediatel...irectors. On,the subject of her appointment Jan Gr...xciting opportunity for me. The Company has done a...linical trials. I expect the next,foreseeable futu...
(Date:7/25/2008)...swire-FirstCall/ -- Caraco Pharmaceutical,Laborato...first quarter of,Fiscal 2009, ended June 30, 2008,...or the corresponding period of Fiscal 2008. This r...er of Fiscal 2008. Pre-tax income grew,to $14.6 mi...ared to a,pre-tax income of $9.6 million during th...
(Date:7/25/2008)...25 /- REvolution Computing will,lead ...R product at the,upcoming BioC 2008 conference in ... REvolution Computing Director of Community, Dr. D... Training Manager, and Martin Morgan of,the Fred H...ting,s BioC lab,will introduce participants to the...
Breaking Biology Technology:BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 2BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 3Jan Gray Joins Resverlogix Board of Directors 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 3Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 4Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 5Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 6Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 7REvolution Computing Offers Hands-On Tutorial of NWS Parallel Computing Environment at BioC 2008 2
...its of switching to voice over Internet protocol (...at the Italian Community Center in Milwaukee. Near... users share their experiences with VoIP. , ,Clear...erry Rocco, Cisco Systems, and Pat Scheckel, VoIP ...Brian Carlson, manager network/communications for ...
...ence faculty at the University of Wisconsin-Eau Cl...h more opportunities to work on research relating ...e university to assist local industries. , ,UW-Eau...ll support research, facilitate collaboration amon...ractions between the university and local industri...
...Julius truly cares about me. He often sends me sto...as for how to buy prescription drugs on the cheap....duction. Ursula seems more interested in enlargeme...up in the From line of my e-mail every day, usuall...in the morning is cleaning out unsolicited message...
...roadcast Systems and Madison-based MyWeather LLC...tion that alerts for breaking news and severe weat...ated television stations. , ,Powered by MyWeather ...imely information to people while they are at work... Desktop Alert to proactively grab viewers attenti...
Other Biology Technology:VoIP: Are we there yet? 2UW-Eau Claire creates Materials Science Center 2UW-Eau Claire creates Materials Science Center 3Putting spam back in the can wont be all that easy 2
(Date:7/24/2008)...tate University College of Medicine, Hershey, Penn...uimod, a clinically important immune response modi... is dependent on the Opioid Growth Factor (OGF)-OG...very, reported in the August 08 issue of Experime...into a widely used drug that may lead to developme...
(Date:7/24/2008)... talk, they might tell potential suitors, "I like ...come slither look. But worms send their valentines...al code researchers are now cracking, according to...nal Nature . , Scientists from the University ...titute of Technology and the U.S. Department of Ag...
(Date:7/24/2008)...uced carbon storage in western U.S. forests , A...entury has caused a widespread increase in fire-in...stems growing on trees within western U.S. forests...re thought to account for much of North America,s ...ound biomass, Fellows and Goulden compare Californ...
(Date:7/23/2008)...together internationally renowned scientists from ...apan, Australia and India to address ancient micr...e are bringing together the world,s best scientist...izer J. William Schopf, founder and director of th...cs, Center for the Study of Evolution and the Orig...
Breaking Biology News(10 mins):Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway 2Mate or hibernate? That's the question worm pheromones answer 2Mate or hibernate? That's the question worm pheromones answer 3AGU journal highlights -- July 23, 2008 2AGU journal highlights -- July 23, 2008 3AGU journal highlights -- July 23, 2008 4AGU journal highlights -- July 23, 2008 5AGU journal highlights -- July 23, 2008 6AGU journal highlights -- July 23, 2008 7AGU journal highlights -- July 23, 2008 8UCLA 'world summit' to explore ancient life on Earth, and beyond 2King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 1King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 2King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 3King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 4King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 5King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 6Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 1Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 2Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 3Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 4Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 5Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 6Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 7Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 8Amylin Pharmaceuticals to Webcast Conference Call 5055 1Amylin Pharmaceuticals to Webcast Conference Call 5055 2Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman 26 Renshaw Healthcare Conference 1603 1Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman 26 Renshaw Healthcare Conference 1603 2
...s has,found the first clear evidence that the proc...ility to recognize and respond to a million,differ...f genes whose,only apparent function is to jump ar...ially cut themselves out of the genetic material, ...ght have been borrowed by cells,needing to build m...
...or of Research at the Molecular Sciences Institut... approach to simulation of intracellular,biochemic...Biotechnology.,The research article, entitled "Au...ith Moleculizer 1.0" (pdf) ,describes MSI,s discre...f the thousands of complex species formed from pat...
...em the rising rate of HIV infection, warn two seni...An estimated 38 million people worldwide, includin...IV, and a record 4.8 million became infected in 20...ncrease is socioeconomic, but the increase also re...s. , For instance, the search for a vaccine agains...
...al nervous system (CNS), where it influences neuro...an now use microarray technology to study brain fu...ed in the February issue of Alcoholism: Clinical &...alcohol on what is called "gene expression" in the... have exactly the same deoxyribonucleic acid (DNA)...
Other Biology News:Jumping gene helps explain immune system's abilities 2Jumping gene helps explain immune system's abilities 3MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 2MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 3Alcohol's effects on gene expression in the central nervous system 2Alcohol's effects on gene expression in the central nervous system 3Alcohol's effects on gene expression in the central nervous system 4
Cytofix/Cytoperm Kit 250 Tests
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:
Anti-MAGE-D2/NRAGE-Like 2b GenBank Accession Number : NM_201222 Immunogen : peptide (C-QSQENQDTRPKVKAKK), corresponding to amino acids 161-176 of human MAGE-D2/NRAGE-Like 2b Formulation: antiserum
Request Info
Biology Products: